Indivior PLC (INDV)
NASDAQ: INDV · Real-Time Price · USD
22.97
+0.13 (0.57%)
At close: Aug 13, 2025, 4:00 PM
23.04
+0.07 (0.30%)
After-hours: Aug 13, 2025, 4:17 PM EDT
Indivior Revenue
Indivior had revenue of $302.00M in the quarter ending June 30, 2025, with 1.00% growth. This brings the company's revenue in the last twelve months to $1.17B, up 2.27% year-over-year. In the year 2024, Indivior had annual revenue of $1.19B with 8.69% growth.
Revenue (ttm)
$1.17B
Revenue Growth
+2.27%
P/S Ratio
2.48
Revenue / Employee
$1,116,080
Employees
1,051
Market Cap
2.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 95.00M | 8.69% |
| Dec 31, 2023 | 1.09B | 192.00M | 21.31% |
| Dec 31, 2022 | 901.00M | 110.00M | 13.91% |
| Dec 31, 2021 | 791.00M | 144.00M | 22.26% |
| Dec 31, 2020 | 647.00M | -138.00M | -17.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INDV News
- 7 days ago - Indivior's Strategic Turnaround Gains Traction Post-Q2 2025 - Seeking Alpha
- 12 days ago - Indivior PLC (INDV) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance - PRNewsWire
- 19 days ago - Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained - PRNewsWire
- 21 days ago - Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder - PRNewsWire
- 27 days ago - Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st - PRNewsWire
- 5 weeks ago - Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs - PRNewsWire
- 6 weeks ago - Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes - PRNewsWire